American Board of Internal Medicine - Medical Oncology
Education & Training
1990, University of Mississippi
Medical / Professional School(s)
1994, University of Mississippi Medical Center
1995, Internal Medicine - University of Mississippi Medical Center and School of Medicine
1997, Internal Medicine - University of Mississippi Medical Center and School of Medicine
2000, Hematology/Oncology - Beth Israel Deaconess Medical Center
2002, Hematology/Oncology - Beth Israel Deaconess Medical Center
Bone and Soft Tissue Cancer (Sarcoma), Melanoma, Squamous Cell Carcinoma of Skin (Non-surgical/Metastatic), Cancer Immunotherapy, Basal Cell Carcinoma of Skin (Non-surgical/Metastatic), Merkel Cell Carcinoma (Non-surgical/Metastatic)
UH Cleveland Medical Center
Department of Medicine-Hematology and Oncology
11100 Euclid Ave
UH Chagrin Highlands Health Center
3909 Orange Pl
Seidman Cancer Center, Ste 1100
Patient Satisfaction Reviews
About Our Survey
At University Hospitals, we believe in providing patients with all the information they need to make educated decisions
about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent
patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians.
We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for
every individual who sees a UH doctor.
There are no comments for this practitioner.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2015, Henry Koon, MD disclosed the following Outside Relationships with Industry:
Bristol Myers Squibb - Consulting
Genentech, Inc. - Consulting
Merck & Co. Inc. - Consulting
Prometheus - Consulting